Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Purpose of Review
Lipoprotein(a) is an important causal risk factor for cardiovascular disease but currently no available medication effectively reduces lipoprotein(a). This review discusses recent findings regarding lipoprotein(a) as a causal risk factor and therapeutic target in cardiovascular disease, it reviews current clinical recommendations, and summarizes new lipoprotein(a) lowering drugs.
Recent Findings
Epidemiological and genetic studies have established lipoprotein(a) as a causal risk factor for cardiovascular disease and mortality. Guidelines worldwide now recommend lipoprotein(a) to be measured once in a lifetime, to offer patients with high lipoprotein(a) lifestyle advise and initiate other cardiovascular medications. Clinical trials including antisense oligonucleotides, small interfering RNAs, and an oral lipoprotein(a) inhibitor have shown great effect on lowering lipoprotein(a) with reductions up to 106%, without any major adverse effects.
Summary
Recent clinical phase 1 and 2 trials show encouraging results and ongoing phase 3 trials will hopefully result in the introduction of specific lipoprotein(a) lowering drugs to lower the risk of cardiovascular disease.
Lipoprotein(a) is an important causal risk factor for cardiovascular disease but currently no available medication effectively reduces lipoprotein(a). This review discusses recent findings regarding lipoprotein(a) as a causal risk factor and therapeutic target in cardiovascular disease, it reviews current clinical recommendations, and summarizes new lipoprotein(a) lowering drugs.
Recent Findings
Epidemiological and genetic studies have established lipoprotein(a) as a causal risk factor for cardiovascular disease and mortality. Guidelines worldwide now recommend lipoprotein(a) to be measured once in a lifetime, to offer patients with high lipoprotein(a) lifestyle advise and initiate other cardiovascular medications. Clinical trials including antisense oligonucleotides, small interfering RNAs, and an oral lipoprotein(a) inhibitor have shown great effect on lowering lipoprotein(a) with reductions up to 106%, without any major adverse effects.
Summary
Recent clinical phase 1 and 2 trials show encouraging results and ongoing phase 3 trials will hopefully result in the introduction of specific lipoprotein(a) lowering drugs to lower the risk of cardiovascular disease.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Current Atherosclerosis Reports |
| Vol/bind | 26 |
| Udgave nummer | 4 |
| Sider (fra-til) | 111-118 |
| Antal sider | 8 |
| ISSN | 1523-3804 |
| DOI | |
| Status | Udgivet - 2024 |
Bibliografisk note
Funding Information:
Novo Nordisk Foundation (grant NNF21OC0071977) (ABW), Aase and Ejnar Danielsen Fund (BGN), Independent Research Fund Denmark (BGN). The funders had no role in the design of the study or in the collection, analysis, interpretation of data, writing the manuscript, or the decision to submit the article for publication.
Publisher Copyright:
© 2024, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
ID: 382983315